105 related articles for article (PubMed ID: 1681035)
1. Cannabinoid receptor-regulated cyclic AMP accumulation in the rat striatum.
Bidaut-Russell M; Howlett AC
J Neurochem; 1991 Nov; 57(5):1769-73. PubMed ID: 1681035
[TBL] [Abstract][Full Text] [Related]
2. Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum.
Meschler JP; Howlett AC
Neuropharmacology; 2001 Jun; 40(7):918-26. PubMed ID: 11378162
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D-2 receptors inhibit D-1 stimulated cyclic AMP accumulation in striatum but not limbic forebrain.
Kelly E; Nahorski SR
Naunyn Schmiedebergs Arch Pharmacol; 1987 May; 335(5):508-12. PubMed ID: 2441268
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain.
Bidaut-Russell M; Devane WA; Howlett AC
J Neurochem; 1990 Jul; 55(1):21-6. PubMed ID: 2162376
[TBL] [Abstract][Full Text] [Related]
5. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation.
Thomas KL; Rose S; Jenner P; Marsden CD
Biochem Pharmacol; 1992 Jul; 44(1):73-82. PubMed ID: 1321630
[TBL] [Abstract][Full Text] [Related]
6. Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum.
Thomas KL; Rose S; Jenner P; Marsden CD
Biochem Pharmacol; 1992 Jul; 44(1):83-91. PubMed ID: 1321631
[TBL] [Abstract][Full Text] [Related]
7. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
[TBL] [Abstract][Full Text] [Related]
8. Specific inhibition of dopamine D-1-mediated cyclic AMP formation by dopamine D-2, muscarinic cholinergic, and opiate receptor stimulation in rat striatal slices.
Kelly E; Nahorski SR
J Neurochem; 1986 Nov; 47(5):1512-6. PubMed ID: 2428936
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
Engber TM; Marin C; Susel Z; Chase TN
Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
[TBL] [Abstract][Full Text] [Related]
10. The effect of dopamine D1 and D2 receptor agonists on inositol phosphate turnover in rat striatal slices.
Gupta SK; Mishra RK
Biochem Int; 1990 Dec; 22(5):887-94. PubMed ID: 1983069
[TBL] [Abstract][Full Text] [Related]
11. Role of N-methyl-D-aspartate receptors in dopamine D1-, but not D2-, mediated changes in striatal and accumbens neurotensin systems.
Singh NA; Bush LG; Gibb JW; Hanson GR
Brain Res; 1992 Feb; 571(2):260-4. PubMed ID: 1351780
[TBL] [Abstract][Full Text] [Related]
12. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
13. Further evidence against the coupling of dopamine receptors to phosphoinositide hydrolysis in rat striatum.
Rubinstein JE; Hitzemann RJ
Biochem Pharmacol; 1990 Jun; 39(12):1965-70. PubMed ID: 1972328
[TBL] [Abstract][Full Text] [Related]
14. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
Giorgi O; Biggio G
Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
[TBL] [Abstract][Full Text] [Related]
15. Dopamine control of seizure propagation: intranigral dopamine D1 agonist SKF-38393 enhances susceptibility to seizures.
Turski WA; Cavalheiro EA; Ikonomidou C; Bortolotto ZA; Klockgether T; Turski L
Synapse; 1990; 5(2):113-9. PubMed ID: 2137942
[TBL] [Abstract][Full Text] [Related]
16. The use of cyclic AMP efflux studies in attempts to determine the effects of morphine on cyclic AMP formation in striatal slices.
Headley PM; O'Shaughnessy CT
Neuropharmacology; 1986 Aug; 25(8):919-22. PubMed ID: 3022183
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.
Engber TM; Boldry RC; Kuo S; Chase TN
Brain Res; 1992 May; 581(2):261-8. PubMed ID: 1356580
[TBL] [Abstract][Full Text] [Related]
18. Striatal Fos expression is indicative of dopamine D1/D2 synergism and receptor supersensitivity.
LaHoste GJ; Yu J; Marshall JF
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7451-5. PubMed ID: 8102797
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of dopamine agonist-induced phosphoinositide hydrolysis by concomitant stimulation of cyclic AMP formation in brain slices.
Undie AS; Friedman E
J Neurochem; 1994 Jul; 63(1):222-30. PubMed ID: 7911510
[TBL] [Abstract][Full Text] [Related]
20. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
Hu XT; White FJ
Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
